Načítá se...
Immune signature-based hepatocellular carcinoma subtypes may provide novel insights into therapy and prognosis predictions
BACKGROUND: Hepatocellular carcinoma (HCC) has a poor prognosis and has become the sixth most common malignancy worldwide due to its high incidence. Advanced approaches to therapy, including immunotherapeutic strategies, have played crucial roles in decreasing recurrence rates and improving clinical...
Uloženo v:
| Vydáno v: | Cancer Cell Int |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8243542/ https://ncbi.nlm.nih.gov/pubmed/34193146 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-021-02033-4 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|